

Circulating Tumor Cell Market Updates 2024 : Asia-Pacific is anticipated to Grow at the Highest CAGR During 2021-2031

North America acquired the major circulating tumor cell market share of the circulating tumor cell market in 2021.


WILMINGTON, DELAWARE , UNITED STATES, June 18, 2024

/EINPresswire.com/ -- Allied Market Research published a report, titled,

"[Circulating Tumor Cell Market](#) by Technology (CTC Detection and Enrichment Method, CTC Direct Detection Methods, CTC Analysis), by Application (Clinical, Research), by End Users (Hospital and Clinics, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031".

According to the report, the global [circulating tumor cell](#) industry generated \$1.1 billion in 2021, and is anticipated to generate \$5.9 billion by 2031, witnessing a CAGR of 18.0% from 2022 to 2031.

According to the report, the global [circulating tumor cell](#) industry generated \$1.1 billion in 2021, and is anticipated to generate \$5.9 billion by 2031, witnessing a CAGR of 18.0% from 2022 to 2031.



Circulating Tumor Cell Market

“

The global circulating tumor cell market size was valued at \$1.1 billion in 2021, and is projected to reach \$5.9 billion by 2031, growing at a CAGR of 18% from 2022 to 2031.”

Allied Market Research

Circulating tumor cells (CTCs) are cells that detach from primary tumors and circulate in the patient's bloodstream. Recently, CTCs have been recognized as valuable biomarkers for the prognostic, diagnostic, and therapeutic response monitoring of cancer patients. These cells are rare, typically found at a concentration of one CTC per milliliter of peripheral blood, amidst approximately 1 million white blood cells and 1 billion red blood cells. Due to their rarity, detecting CTCs presents significant challenges. However, advancements in detection

techniques, particularly those using integrated microfluidics and nanomaterial-based platforms, have improved selectivity and simplified the detection process.

[sample/A11918](https://www.alliedmarketresearch.com/sample/A11918)

The major trends driving the growth of the circulating tumor cell market include the rising number of cancer cases globally. CTC detection is primarily used for early cancer diagnosis, making these techniques increasingly important for cancer diagnosis and prognosis. Consequently, there is a growing demand for products such as kits and instruments used in CTC detection, further expanding the market.

Technological advancements in diagnostics and treatment, an increase in the number of cancer cases, greater awareness about CTCs and their role in cancer diagnosis, and a rise in research and development activities and clinical trials are driving the growth of the global circulating tumor cell market. However, the high cost associated with CTC testing, due to the expensive instruments required, is expected to hinder market growth. On the other hand, increased investment by key market players in developing countries and the adoption of various strategic initiatives by these players are anticipated to present new opportunities in the coming years.

Based on application, the clinical segment held the highest market share in 2021, accounting for more than two-thirds of the global circulating tumor cell market, and is expected to maintain its leadership status throughout the forecast period. This dominance is due to the increasing adoption of CTC detection techniques in cancer diagnosis and the rising number of cancer cases, including breast, prostate, and colon cancer. However, the research segment is projected to exhibit the highest compound annual growth rate (CAGR) of 18.6% from 2022 to 2031, driven by a surge in research and development activities focused on CTC detection and cancer diagnosis.

For more information, visit <https://www.alliedmarketresearch.com/purchase-enquiry/A11918>

Key players in the market include:

- Miltenyi Biotec
- Precision Medicine Group LLC
- Menarini Group
- SRI International
- Biocept, Inc.
- QIAGEN
- Greiner AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- STEMCELL Technologies Inc.

For more information, visit <https://www.alliedmarketresearch.com/respiratory-disposables-market-A11235>

For more information, visit <https://www.alliedmarketresearch.com/respiratory-disposables-market-A11235>

For more information, visit <https://www.alliedmarketresearch.com/sarcopenia-treatment-market-A10526>

David Correa
Allied Market Research
+1 800-792-5285
[email us here](#)
Visit us on social media:
[Facebook](#)
[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/720903866>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.